Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study

Mariusz Dąbrowski 1
1 - Department of Medicine, Institute of Nursing and Health Sciences, University of Rzeszow, Poland; Diabetic Outpatient Clinic, NZOZ Beta-Med, Rzeszow, Poland
Ann Agric Environ Med
2013; 20 (1):
ICID: 1041710
Article type: Original article
 
 
Introduction: Type 2 diabetes is associated with an increased risk of some types of cancer. Diabetes treatment may also modify cancer risk.
Objective: The aim of this retrospective, case-control study was to assess whether HbA1c level and use of anti-diabetic drugs are associated with cancer development in a diabetic population.
Materials and methods: The case group consisted of 53 patients who developed cancer after diagnosis of diabetes. They were compared with 53 diabetic subjects without cancer, strictly matched to a case group by age and gender. In both groups – apart from HbA1c and diabetes treatment – demographic data, smoking habits, comorbidities, BMI, diabetes duration, use of aspirin, antihypertensive and hypolipemic drugs were also analyzed.
Results: Patients with cancer had a significantly higher mean HbA1c value compared with the control group, 7.83±1.26% vs. 7.30±1.08%, respectively (p=0.022). The distribution of patients in four HbA1c categories (<7.0, 7.0-7.9, 8.0-8.9 and ≥9.0%) was significantly different between the two groups (p=0.031). The probability of cancer was higher among patients with HbA1c value ≥8.0 % OR 3.160 (95% CI 1.342-7.440), p=0.013, and lower among patients using metformin, OR 0.228 (95% CI 0.083-0.633), p=0.006. The number of insulin users, insulin dose, duration of insulin treatment, and use of other anti-diabetic drugs were not significantly different between the two groups. Also, no significant differences were found between the two groups regarding other variables.
Conclusions: The presented case-control study indicated an important role of metabolic control and confirmed the protective role of metformin in reducing cancer risk among patients with type 2 diabetes. Contrary to other studies, insulin use was not associated with a higher risk of cancer. Other anti-diabetic drugs appeared to have a neutral impact on cancer development.
PMID 23540224 - click here to show this article in PubMed
  FULL TEXT STATS

Recommend this article to:

Name:
E-mail:
From:
Language:


Related articles in IndexCopernicus™
     obesity [45 related records]
     insulin [18 related records]
     Metformin [3 related records]
     glycated hemoglobin [33 related records]
     cancer [30 related records]
     type 2 diabetes [243 related records]



 

Related articles

M Amirrood, M Taghdisi,
The Role Of Eating Attitude On Obesity-Related Eat...
Background and Aim: Identifying obesity-related eating behavior predictors especially in women, who have a key role in their family's food basket, has a great importance in the prevention of obesity. The purpose of the present study is to determine t...
ABSTRACT
A Çeltik, B Akıncı,
Mean Platelet Volume in Women with Gestational Dia...
Purpose: Mean platelet volume (MPV) is an indicator of platelet activation which plays an important role in the pathogenesis of atherosclerosis. The purpose of this study was to compare MPV values in patients with previous gestational diabetes (pGDM...
ABSTRACT
, ,
Evaluation of Oxidative Stress and Antioxidant Sta...
 Aim: To evaluate serum Total Antioxidant Capacity(TAC) and serum Total Peroxidase (TP) Oxidative Stress Index (OSI) and measure its correlation with Glycosylated Hemoglobin (GHM). Study design: an analytical case control study. Place and Durati...
ABSTRACT